The utilization of the large unstained cell (LUC) parameter in lymphoid, haematopoietic and related tissue’s malignant neoplasms


gök g., Erdogan S., ASUTAY E., Yilmaz G., EREL O., Yılmaz F. M.

The European Research Journal, vol.11, no.4, pp.732-740, 2025 (Peer-Reviewed Journal) identifier

  • Publication Type: Article / Article
  • Volume: 11 Issue: 4
  • Publication Date: 2025
  • Doi Number: 10.18621/eurj.1625710
  • Journal Name: The European Research Journal
  • Journal Indexes: Academic Search Premier, EMBASE, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.732-740
  • Ankara Yıldırım Beyazıt University Affiliated: Yes

Abstract

Objectives: Large unstained cells (LUCs) are a differential count parameter reported by routine hematology analysis, and LUC percentages (LUC%) reflect active lymphocytes and peroxidase-negative cells. We aimed the evaluate the LUC% parameter in routine practice towards malignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic, and related tissue. Methods: LUC analysis was performed with Siemens ADVIA® 2120 Hematology System. Data were obtained from Ankara Bilkent City Hospital’s laboratory information system. Results: A statistical difference in the LUC % data in the case of LUC % <4.5 and LUC % ≥4.5 among preliminary diagnoses was observed (P<0.001). According to the Kruskal-Wallis test, a statistical difference was observed between preliminary diagnosis and LUC % values (P<0.001). The One-way ANOVA test with Bonferroni correction was performed for post hoc multiple comparisons of the preliminary diagnosis among LUC%. LUC% was higher in Hodgkin Lymphoma patients than Myeloid leukaemia patients (P=0.002). LUC % was higher in the Lymphoid leukaemia patients than in the patients with Hodgkin lymphoma (P<0.001), Other and unspecified types of non-Hodgkin lymphoma (P<0.001), Multiple myeloma and malignant plasma cell neoplasms (P<0.001). LUC% was higher in patients with leukemia unspecified cell type than Hodgkin lymphoma (P<0.001), Follicular lymphoma (P<0.001), Non-follicular lymphoma (P<0.001), Mature T-Cell and Natural Killer Cell lymphomas (P<0.001), Other and unspecified types of non-Hodgkin lymphoma (P<0.001), Malignant immunoproliferative diseases (P<0.001), Multiple myeloma and malignant plasma cell neoplasms (P<0.001), Lymphoid leukaemia (P<0.001), Myeloid leukaemia (P<0.001), Other leukaemias of specified cell type patients (P<0.001). Conclusions: The present study underscores the importance of LUC% in line with ICD-10 and may provide ideas for new research. Prospective studies including patient and control groups may be useful in assessing LUC%.